Login to Your Account

Xenikos raises $30M for acute GVHD candidate

By Nuala Moran
Staff Writer

Wednesday, May 16, 2018

LONDON – Xenikos BV has taken a huge step toward commercializing its T-Guard treatment for acute graft-vs.-host disease (GVHD), closing a $30 million series B round to fund U.S. and European phase III trials of the antibody-drug conjugate.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription